Insider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Director Sells $100,305.00 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) Director Michael Gilman sold 3,375 shares of the stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $29.72, for a total value of $100,305.00. Following the transaction, the director now directly owns 55,216 shares in the company, valued at approximately $1,641,019.52. This represents a 5.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Scholar Rock Stock Down 2.4%

Shares of NASDAQ:SRRK opened at $29.13 on Monday. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of -12.40 and a beta of 0.37. The company’s fifty day moving average is $30.38 and its two-hundred day moving average is $36.10. Scholar Rock Holding Co. has a 1-year low of $6.76 and a 1-year high of $46.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the company posted ($0.59) EPS. Equities analysts anticipate that Scholar Rock Holding Co. will post -2.42 EPS for the current year.

Analyst Ratings Changes

Separately, Wedbush reiterated an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a report on Wednesday, May 14th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $42.67.

Institutional Investors Weigh In On Scholar Rock

A number of institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in Scholar Rock by 33.7% during the fourth quarter. FMR LLC now owns 13,635,261 shares of the company’s stock worth $589,316,000 after acquiring an additional 3,439,215 shares during the period. Marshall Wace LLP grew its stake in shares of Scholar Rock by 1,283.7% in the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company’s stock worth $127,301,000 after purchasing an additional 2,732,546 shares during the last quarter. Norges Bank bought a new stake in shares of Scholar Rock in the 4th quarter worth approximately $86,043,000. Fairmount Funds Management LLC bought a new stake in shares of Scholar Rock in the 4th quarter worth approximately $84,839,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in Scholar Rock during the fourth quarter valued at approximately $68,930,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.